Mechanical ventilation

Inspira Technologies Reveals the AXT - An Intelligent System that Directly Oxygenates Blood for Respiratory Care

Retrieved on: 
Thursday, December 10, 2020
Medical specialties, Clinical medicine, Medicine, Intensive care medicine, Respiratory therapy, Emergency medicine, Mechanical ventilation, Axt

Last week, Inspira announced that it filed a patent application for its new AXT system, as a preventive treatment to avoid the use of invasive mechanical ventilation.

Key Points: 
  • Last week, Inspira announced that it filed a patent application for its new AXT system, as a preventive treatment to avoid the use of invasive mechanical ventilation.
  • The AXT system is five times smaller than invasive mechanical ventilation machines and allows, for the first time, mobility, simplicity, and flexibility.
  • "Inspira's AXT system is a fundamental game changer in the field of blood oxygenation," commented Yigal Kassif, MD.
  • The Company has developed a breakthrough respiratory support system, the AXT, which directly oxygenates blood and immediately elevates and stabilizes patient oxygen levels.

Diaphragm Strength Improved by Over Three Hundred Percent Using the Lungpacer® System over Standard of Care in Multicenter, Randomized Controlled Trial

Retrieved on: 
Wednesday, December 9, 2020
Medical Supplies, Medical devices, Health, Infectious diseases, Hospitals, Clinical trials, Medical specialties, Respiratory therapy, Medicine, Health care, Mechanical ventilation, Ventilator

RESCUE 2 was a 30-day multi-center, randomized, controlled feasibility trial (RCT) evaluating the Lungpacer System as a weaning therapy, and compared Standard of Care (SoC) to Lungpacer plus SoC for patients on long-term mechanical ventilation.

Key Points: 
  • RESCUE 2 was a 30-day multi-center, randomized, controlled feasibility trial (RCT) evaluating the Lungpacer System as a weaning therapy, and compared Standard of Care (SoC) to Lungpacer plus SoC for patients on long-term mechanical ventilation.
  • Compared to baseline, diaphragm thickening fraction improved by 35 percent and 30 percent more for the right and left hemidiaphragms, respectively, in the Lungpacer therapy group compared to SoC.
  • Ventilators use positive pressure to force air into the lungs, leaving the diaphragm unused and causing it to weaken quickly.
  • Lungpacer, Weaning Solution, Lungpacer DPT System, Lungpacer DPT, LIVE Catheter are registered trademarks of Lungpacer Medical.

Inspira Technologies Files U.S. Patent Application for its Innovative Respiratory Support Technology; Engages Leading U.S. Investment Bank for NASDAQ Listing

Retrieved on: 
Thursday, December 3, 2020
Medical specialties, Medicine, Clinical medicine, Intensive care medicine, Respiratory therapy, Medical emergencies, Respiratory diseases, Emergency medicine, Mechanical ventilation, Pulse oximetry, Respiratory failure

"Our direct blood oxygenation system provides a solution for the high risks and costs associated with existing ventilation technology.

Key Points: 
  • "Our direct blood oxygenation system provides a solution for the high risks and costs associated with existing ventilation technology.
  • The patent encompasses the technologies developed by Inspira, enabling the early treatment of patients with respiratory failure, who would otherwise be treated with invasive mechanical ventilation.
  • Inspira Technologies is an innovative medical technology company in the respiratory support space.
  • The Company has developed a breakthrough respiratory support system, the AXT, which directly oxygenates blood and immediately elevates and stabilizes patient oxygen levels.

Global Continuous Positive Airway Pressure Devices Market Report 2020-2027: Increasing Prevalence of Respiratory Disorders and COVIDd-19 Cases Driving Growth

Retrieved on: 
Wednesday, December 2, 2020
Medicine, Clinical medicine, Branches of biology, Sleep disorders, Mechanical ventilation, Medical equipment, Continuous positive airway pressure, Sleep apnea, Positive airway pressure, Colin Sullivan, Sleep surgery

The global continuous positive airway pressure (CPAP) devices market is expected to reach US$ 4,481.41 million by 2027 from US$ 2,462.86 million in 2019.

Key Points: 
  • The global continuous positive airway pressure (CPAP) devices market is expected to reach US$ 4,481.41 million by 2027 from US$ 2,462.86 million in 2019.
  • Growing prevalence of sleep apnea, respiratory disorders, rising number of geriatric population, and increasing prevalence of obesity are the major factors propelling the adoption of CPAP devices.
  • Moreover, continuous positive airway pressure (CPAP) is currently the most widespread and effective therapy for respiratory disorders.
  • Based on end user, the continuous positive airway pressure (CPAP) devices market has been segmented into emergency health departments and hospitals.

Clinical Trial Shows Faster Recovery and Respiratory Improvement in Critically Ill COVID-19 Patients, Multi Radiance Medical to Apply for FDA Emergency Use Authorization

Retrieved on: 
Tuesday, December 1, 2020
Medical devices, FDA, Health, Infectious diseases, Clinical trials, Biotechnology, Medical specialties, Health sciences, Health, Intensive care medicine, Respiratory therapy, Acute respiratory distress syndrome, Respiratory physiology, Therapy, Pain management, Food and Drug Administration, Coronavirus disease, Mechanical ventilation

After completing a clinical trial evaluating its super pulsed laser therapy technology to improve respiratory function in critically ill COVID-19 patients, medical device manufacturer Multi Radiance Medical (MRM) prepares to apply for emergency use authorization with the Food and Drug Administration (FDA).

Key Points: 
  • After completing a clinical trial evaluating its super pulsed laser therapy technology to improve respiratory function in critically ill COVID-19 patients, medical device manufacturer Multi Radiance Medical (MRM) prepares to apply for emergency use authorization with the Food and Drug Administration (FDA).
  • The trial results show that MRM super pulsed laser therapy decreased invasive intubation time/need by 18% overall, and decreased mechanical ventilation time/need overall by 23%.
  • This is the first clinical evidence that super pulsed laser therapy can significantly improve the ARDS symptoms of the critically ill.
  • Multi Radiance Medical manufactures FDA-cleared super pulsed laser therapy devices for pain management and accelerated recovery.

Mechanical Ventilator Market to Reach $12.54 Bn, Globally, at CAGR 16.5% by 2027: AMR

Retrieved on: 
Wednesday, November 25, 2020
Medical specialties, Medicine, Health, Respiratory therapy, Intensive care medicine, Occupational safety and health, Ventilator, Mechanical ventilation, COVID-19 pandemic, Coronavirus disease, Open-source ventilator, Prone ventilation

"According to the report published by Allied Market Research, the global mechanical ventilator market generated $2.99 billion in 2019, and is estimated to reach $12.54 billion by 2027, registering a CAGR of 16.5% from 2020 to 2027.

Key Points: 
  • "According to the report published by Allied Market Research, the global mechanical ventilator market generated $2.99 billion in 2019, and is estimated to reach $12.54 billion by 2027, registering a CAGR of 16.5% from 2020 to 2027.
  • Conversely, high cost of mechanical ventilators and increase in incidences of ventilators-associated pneumonia restrain the market growth.
  • The demand for mechanical ventilator has been increased during the Covid-19 pandemic.
  • "Mechanical Ventilation is a bridge between life and death during COVID-19: Supports critically ill patients with acute respiratory failure."

Global Continuous Positive Airway Pressure Devices Market Forecast to 2027 with COVID-19 Impact and Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 25, 2020
Medical devices, Health, Medicine, Clinical medicine, Medical specialties, Mechanical ventilation, Positive airway pressure, Continuous positive airway pressure, Non-invasive ventilation, Ventilator, Modes of mechanical ventilation, Continuous spontaneous ventilation

The "Continuous Positive Airway Pressure Devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; End User; and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Continuous Positive Airway Pressure Devices Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Type; End User; and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The global continuous positive airway pressure (CPAP) devices market is expected to reach US$ 4,481.41 million by 2027 from US$ 2,462.86 million in 2019.
  • Thus, devices such as CPAP, auto-CPAP, and bi-level positive airway pressure (BiPAP or BPAP) are used as an alternative for ventilator devices.
  • Based on end user, the continuous positive airway pressure (CPAP) devices market has been segmented into emergency health departments and hospitals.

REMSleep Patent Application

Retrieved on: 
Friday, November 20, 2020
Medicine, Clinical medicine, Branches of biology, Sleep disorders, Mechanical ventilation, Continuous positive airway pressure, Medical equipment, Sleep apnea, Positive airway pressure, Obstructive sleep apnea, Apnea, Mandibular advancement splint

Tampa, FL, Nov. 20, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --REMSleep Holdings, Inc. (OTC PINK: RMSL): REMSleep receives office action from the United States Patent and Trademark Office ("USPTO") concerning the company's patent application 15/595,990 for its Deltawave CPAP nasal pillows device.

Key Points: 
  • Tampa, FL, Nov. 20, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire --REMSleep Holdings, Inc. (OTC PINK: RMSL): REMSleep receives office action from the United States Patent and Trademark Office ("USPTO") concerning the company's patent application 15/595,990 for its Deltawave CPAP nasal pillows device.
  • REMSleep Holdings, Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients.
  • With over 30 years of collective experience in CPAP therapy, the REMSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance.
  • REMSleep Holdings, Inc. has a new patent pending, innovative sleep apnea product that will meet multiple market demand and be able to reach and address a large percentage of the patient population who continue to struggle with CPAP compliance.

REMSleep Holdings -- Time Line Update

Retrieved on: 
Thursday, November 19, 2020
Medicine, Clinical medicine, Medical specialties, Mechanical ventilation, Sleep disorders, Continuous positive airway pressure, Medical equipment, Positive airway pressure, Sleep apnea, Obstructive sleep apnea, Apnea, Mandibular advancement splint

Tampa, FL, Nov. 19, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- REMSleep Holdings, Inc. (OTC PINK: RMSL) has initiated bio testing requirements for its flagship Deltawave Nasal Pillow Mask.

Key Points: 
  • Tampa, FL, Nov. 19, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- REMSleep Holdings, Inc. (OTC PINK: RMSL) has initiated bio testing requirements for its flagship Deltawave Nasal Pillow Mask.
  • The new 510K is expected to be completed in time for 1st quarter 2021 market distribution.
  • REMSleep Holdings, Inc. is a medical device manufacturer dedicated to forever changing the level of treatment provided to obstructive sleep apnea patients.
  • With over 30 years of collective experience in CPAP therapy, the REMSleep team has extensive knowledge and understanding of CPAP and the challenges of patient compliance.

Shareholder Update

Retrieved on: 
Thursday, November 19, 2020
Medicine, Clinical medicine, Branches of biology, Mechanical ventilation, Sleep disorders, Medical equipment, Continuous positive airway pressure, Sleep apnea, Positive airway pressure

TAMPA, FL, Nov. 19, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- REMSleep Holdings, Inc. (OTC PINK: RMSL) Gives an update on FDA process.

Key Points: 
  • TAMPA, FL, Nov. 19, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- REMSleep Holdings, Inc. (OTC PINK: RMSL) Gives an update on FDA process.
  • The new Deltawave nasal pillows mask evolved from the company's original 510K and CPAP mask, Laminair.
  • The company has since exhausted every means possible to a pathway of using the company's original 510K.
  • Our focus is primarily designing and manufacturing devices and products for the treatment of sleep apnea and other respiratory conditions.